Brief: Akoya Biosciences To Partner With Acrivon Therapeutics For The Clinical Development Of Acrivon’s Proprietary Oncosignature Test Into A Companion Diagnostic
28/06/2022 13:09
June 28 (Reuters) - Akoya Biosciences Inc AKYA.O :
* AKOYA BIOSCIENCES TO PARTNER WITH ACRIVON THERAPEUTICS FOR
THE
CLINICAL DEVELOPMENT OF ACRIVON’S PROPRIETARY ONCOSIGNATURE®
TEST INTO A COMPANION DIAGNOSTIC
* AKOYA BIOSCIENCES INC - ONCOSIGNATURE TEST WILL RUN ON
CO'S
PHENOIMAGER SOLUTION
* AKOYA BIOSCIENCES INC - IN PARTNERSHIP WITH ACRIVON, CO
WILL
DEVELOP, CLINICALLY VALIDATE, AND SEEK REGULATORY CO-APPROVAL
FOR ONCOSIGNATURE TEST
* AKOYA - IN PARTNERSHIP WITH ACRIVON, CO WILL COMMERCIALIZE
TEST
AS EXCLUSIVE PROVIDER OF COMPANION DIAGNOSTIC REQUIRED FOR
PRESCRIBING ACR-368
Source text for Eikon: ID:nGNX6jbD76
Further company coverage: AKYA.O
Recent news on Akoya Biosciences
See all newsBrief: Akoya Biosciences Inc - On May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing
Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Akoya Biosciences Q1 Gross Margin 59.3%
Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Leerink Partners downgrades Quanterix to 'market perform' on Akoya deal risks